Galliven-200

Composition

Each 100 g contains:

Erythromycin thiocyanate 20 g

Description

Galliven-200 is formulated for the treatment of infectious diseases in poultry caused by erythromycin-sensitive bacteria and Mycoplasma species. Erythromycin, a macrolide antibiotic, acts by reversibly binding to the 50S ribosomal subunit, thereby inhibiting transpeptidation and translocation processes, resulting in disrupted protein synthesis and subsequent inhibition of bacterial growth.

Indications

Galliven-200 is indicated for the management of Chronic Respiratory Disease (CRD) associated with Mycoplasma infections, as well as for infectious respiratory diseases in poultry attributable to erythromycin-sensitive bacteria. Target pathogens include Staphylococcus aureus (such as infectious arthritis), Haemophilus paragallinarum (including infectious coryza), and Pasteurella multocida (such as pasteurellosis and pneumonia).

Contraindications

Use is contraindicated in animals with known hypersensitivity to erythromycin, or those suffering from severe hepatic or renal impairment. Concurrent administration with tetracyclines, chloramphenicol, other macrolides, or lincosamides should be avoided.

Side Effects

Hypersensitivity reactions may occur following administration.

Dosage

Administer orally. Poultry: 1 kg per 1000 litres of drinking water for a duration of 3 to 5 days.

Withdrawal Times

• Meat: 3 days
• Eggs: 6 days

Packaging

1000 g